Structure Therapeutics (GPCR) Cash from Financing Activities (2022 - 2026)

Structure Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 315.33% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at $760.0 million (up 47.46% YoY), while the FY2025 annual figure was $762.5 million, up 47.99% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$1.7 million, down from $705.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $705.0 million in Q4 2025, with the low at -$1.7 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is $615000.0 (2024), against an average of $103.3 million.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities soared 173400.67% in 2024, then slumped 315.33% in 2026.
• Structure Therapeutics' Cash from Financing Activities stood at -$316000.0 in 2022, then jumped by 89223.1% to $281.6 million in 2023, then sank by 99.78% to $615000.0 in 2024, then jumped by 114532.03% to $705.0 million in 2025, then sank by 100.25% to -$1.7 million in 2026.
• Business Quant data shows GPCR's Cash from Financing Activities at -$1.7 million in Q1 2026, $705.0 million in Q4 2025, and $56.2 million in Q3 2025.